Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Example Input: The company has since mid-March launched three coronavirus tests, including an antibody test crucial in identifying immunity among people and one that can deliver results within minutes, which was heralded as a game changer by President Donald Trump. Shares of the company were up 6% at $96.48 in morning trading. Despite the strong uptake in coronavirus testing, the cancellation of non-essential surgeries and restrictions on people's movement are expected to severely crimp sales of its medical devices and other lab tests, which contribute to more than half of total quarterly revenue. "(The second quarter) will likely be our toughest quarter in the year, especially for our core lab business, our cardio and neuro businesses," Chief Executive Officer Robert Ford said on a post-earnings call. The company suspended its full-year forecast due to the uncertainty caused by the health crisis and said it expects to provide an update in the second half of the year. Abbott projected a recovery in elective procedures and testing volumes globally from the third quarter and said it was seeing signs of stabilization in China and areas where the outbreak has begun to abate. "We're all hoping for a fast recovery here, but if it takes longer, we'll have strong demand for testing and that will continue to help buffer the impact," Ford said. Elective procedure declines were at the core of Johnson & Johnson's (JNJ.N) decision to cut 2020 forecasts on Tuesday, with recovery expected in the second half of the year. Abbott beat first-quarter earnings expectations as shelter-in-place restrictions imposed by U.S. states boosted demand for nutrition products for children such as PediaSure, lifting sales in the unit by 6.3% to $1.90 billion. Results were also boosted by a strong flu season before the outbreak that helped minimize testing declines and on softer-than-expected COVID-19 impact across businesses, said J.P. Morgan analyst Robbie Marcus. Sales in the diagnostics unit fell nearly 1% to $1.83 billion, while demand for its FreeStyle Libre diabetes monitoring device remained strong fueled by expanded insurance coverage in Japan. Sales of the device surged 60% to over $600 million. Excluding items, the company earned 65 cents per share, beating expectation of 58 cents. Net sales of $7.73 billion also topped estimates of $7.34 billion.
Example Output: Coronavirus test ramp-up to help Abbott weather 'toughest quarter'.

Example Input: The coronavirus, which emerged in China late last year, has decimated global markets as it quickly moves around the world. It appeared poised for a spike in the United States, in part because of more testing to confirm cases. Florida late Sunday declared a public health emergency as it confirmed its first two cases. Trump administration officials worked Sunday to soothe nerves and calm fears that a global recession was looming, arguing that the public and media were over-reacting and saying that stocks would bounce back because the American economy was fundamentally strong. The total number of confirmed cases in the United States is more than 75 with two reported deaths, both in Washington state. Globally there have been more than 87,000 cases and nearly 3,000 deaths in 60 countries, according to the World Health Organization. In the United States, a cluster of cases is centered on a nursing home near Seattle. The Seattle and King County public health department confirmed late Sunday that a man in his 70s who was a resident of the LifeCare long-term care facility in Kirkland and had coronavirus had died the day before. On Saturday, the department had reported the first death of a coronavirus patient in the United States, a man in his 50s who was living in Kirkland - the same city where the nursing home is located. Six of the 10 confirmed coronavirus cases in Washington state have been residents or workers at LifeCare. State officials said an additional 27 residents of the nursing home and 25 staff members were reporting symptoms of the virus, which can be similar to that of the common flu. New York Governor Andrew Cuomo confirmed on Twitter his state's first coronavirus case, a woman in her 30s who caught the virus during a recent trip to Iran and was now in home quarantine. Cuomo did not say where the woman lived, but the New York Times reported she was in the Manhattan borough of New York City, citing state officials. "The patient has respiratory symptoms, but is not in serious condition and has been in a controlled situation since arriving in New York," Cuomo said. Stock markets plunged last week, with an index of global stocks setting its largest weekly fall since the 2008 financial crisis, and more than $5 trillion wiped off the value of stocks worldwide. A key energy conference in Houston that brings together oil ministers and energy firms was canceled on Sunday with the organizers of CERAWeek noting that border health checks were becoming more restrictive and companies had begun barring non-essential travel to protect workers. A world economy conference with Pope Francis due to take place in Italy later this month was also canceled. Trump said on Sunday that travelers to the United States from countries at high risk of coronavirus would be screened before boarding and on arrival, without specifying which countries. Delta Air Lines Inc said on Sunday it was suspending until May flights to Milan in northern Italy, where most of that country's coronavirus cases have been reported. Flights will continue to Rome. American Airlines Group Inc announced a similar move late on Saturday. The United States has 75,000 test kits for coronavirus and will expand that number "radically" in coming weeks, U.S. Health and Human Services Secretary Alex Azar told ABC's "This Week" on Sunday. Vice President Mike Pence, appointed last week to run the White House's coronavirus response, said the government had contracted 3M Co to produce an extra 35 million respiratory masks a month. He urged Americans not to buy the masks, which he said were only needed by healthcare workers. Honeywell International Inc is the other major U.S. mask producer. He also told Fox News that clinical trials of a coronavirus vaccine would start in six weeks but that a vaccine would likely not be available this season. Democrats, who will challenge Trump for the presidency in the Nov. 3 election, have criticized his administration for downplaying the crisis and not preparing for the disease to spread in the United States. Pence said Americans should brace for more cases but that the "vast majority" of those who contracted the disease would recover. "Other than in areas where there are individuals that have been infected with the coronavirus, people need to understand that for the average American, the risk does remain low. We're ready," Pence told NBC's "Meet the Press."
Example Output: Washington state confirms second U.S. coronavirus death; New York reports first case.

Example Input: Although this therapy only exists for patients in clinical trials, we still think cost should have received more than a single word of attention. "The method is complex and costly," the story stated. Our quick review identified a Wall Street Journal article suggesting that the cost could be as high as $500,000 per patient roughly equivalent to a stem cell transplant. The story's focus on the anecdotal success story of one patient, Bill Ludwig, had the potential to confuse readers since his experience was not typical. However, wethink that the story managed to combine his real-life story along with some generalizable information on the treatment success in a straightforward fashion. The story includes these details: Of the first 14 CLL patients given the T-cell therapy, four had their cancers disappear including the first two, who are now about five years cancer-free. Four others got better but then their cancer progressed. And six had no response to the T-cell therapy. In addition to those results, published last week in Science Translational Medicine, the Penn team has orally presented data for a total of 38 CLL patients. Cancer disappeared in nine (24 percent), and temporarily regressed in another nine. We especially liked the last line,"They've never said 'cured.' But 'cancer-free' works for me." The patient, Ludwig, who was ultimately "cancer free," suffered some serious complications. The story talks about these, but we would have preferred more discussion of the overall risks or harms and not just an anecdotal description. Ludwig "suffered catastrophic side effects as his immune system went into overdrive," the story stated. He had to spend time in intensive care with his organs failing. The story is silent on whether many or most patients who received the therapy suffered harms. Researcher Walter Urba says, "Everything we do in oncology is a risk-benefit balance." These clinical trials for T-cell therapy have enrolled a small number of patients nationally, so there is not the typical history of studies in thousands of people that might be available for other treatments. The story clearly describes the small number of subjects treated to date and provides absolute numbers in terms of success and failures of treatment. Researcher Walter Urba gives some context: "I suspect that over time we'll have better T-cell therapies, maybe given with other immune therapies." There is no disease mongering. The story quotes an expert who was not involved with the study. It contrasts statements the researcher made 4 years ago about the treatment with his thoughts following publication of the new findings an interesting comparison. However, we must rate the story Not Satisfactory here for its lack of discussion of funding for the study, which came in part from the pharmaceutical company Novartis. In addition, one of the study authors is a Novartis employee, and the expert mentioned above is a paid consultant to Bristol Myers Squibb, which is also developing immunotherapies. The story does note that "pharmaceutical giant Novartis partnered with Penn, aiming to commercialize the breakthrough," but the extent of commercial involvement in the study that's discussed isn't clear. The story provides a bit of insight into the tough road that many patients with leukemia travel: "The retired corrections officer from Bridgeton, N.J., was losing his decadelong battle with CLL when he agreed to try the novel therapy in August 2010. "I didn't hesitate because I had no options left," he recalled last week. "And also, these people at Penn had been so wonderful to me and my family for 10 years.".."CLL typically progresses more slowly than other types of leukemia, and may be held in check for years with chemotherapy." Since the story does at least mention one alternative approach chemotherapy we'll give the benefit of the doubt. However, we would have preferred to see just a bit more information on alternative strategies. Single and combination drug therapies are available along with stem cell transplantation; these are all existing alternative to T-cell therapies. The story is clearly about clinical trials only open to select patients. The story explains how the T-cell therapy is novel. The story shows independent reporting beyond any news release.
Example Output:
T-cell therapy results more modest than hoped for chronic leukemia